Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05123365 · ClinicalTrials.gov registry record · Phase 1
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
A Phase 1 study of Myelofibrosis and Myeloproliferative Neoplasm, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 2
- Study locations
NCT05123365: Recruiting Phase 1 study of Myelofibrosis and Myeloproliferative Neoplasm, sponsored by University of California, Irvine.
NCT05123365 is a Phase 1 study of Myelofibrosis and Myeloproliferative Neoplasm that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 27 participants, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05123365, a Phase 1 study of Myelofibrosis and Myeloproliferative Neoplasm, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).
Primary Outcome
Determination of the optimal biological dose (OBD) will be utilized to evaluate the safety and tolerability of N-AC as a treatment for patients with MPN. Optimal biological dose is defined as the therapeutic dose that possesses the highest efficacy probability while inducing acceptable toxicity
Conditions Studied
Interventions
- DRUG N-Acetylcysteine
Study Locations (2)
California
- University of California, Irvine - Irvine
- Chao Family Comprehensive Cancer Center, University of California, Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-01-03 |
| Est. Completion | 2026-11-15 |
| Phase | Phase 1 |
What NCT05123365 shows while recruiting
NCT05123365 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (86% lower).
The record links to 5 conditions, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which N-Acetylcysteine is the first listed.
NCT05123365 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05123365 about?
NCT05123365 is a clinical study titled "An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms". This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).
What is the current status of trial NCT05123365?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2022-01-03. Estimated completion is 2026-11-15.
What conditions does trial NCT05123365 study?
This clinical trial studies the following conditions: Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera, Essential Thrombocythemia, MPN.
What interventions are being tested in trial NCT05123365?
The interventions under investigation include: N-Acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT05123365?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05123365 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05123365's enrollment target sits among peer trials
27 44th of 61 higher than 18 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI